



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72, 73

(48) Corrigendum issued on:
19.05.2021 Bulletin 2021/20

(45) Date of publication and mention
of the grant of the patent:
03.03.2021 Bulletin 2021/09

(21) Application number: **14794569.5**

(22) Date of filing: **08.05.2014**

(51) Int Cl.:
A61K 33/24 ^(2019.01) **A61K 9/14** ^(2006.01)
A61K 9/16 ^(2006.01) **A61K 9/10** ^(2006.01)
A61P 3/06 ^(2006.01) **A61P 21/04** ^(2006.01)
A61P 25/00 ^(2006.01) **A61P 25/02** ^(2006.01)
A61P 25/04 ^(2006.01) **A61P 25/28** ^(2006.01)
A61P 27/02 ^(2006.01) **A61P 43/00** ^(2006.01)

(86) International application number:
PCT/US2014/037280

(87) International publication number:
WO 2014/182888 (13.11.2014 Gazette 2014/46)

(54) **METHODS AND TREATMENT FOR CERTAIN DEMYELINATION AND DYSMYELINATION-BASED DISORDERS AND/OR PROMOTING REMYELINATION**

VERFAHREN UND BEHANDLUNG FÜR BESTIMMTE DEMYELISIERUNGS- UND
DYSMYELINIERUNGS-VERMITTELTE ERKRANKUNGEN UND ODER ZUR
REMYELINISIERUNGSFÖRDERUNG

MÉTHODES ET TRAITEMENT POUR CERTAINS TROUBLES DE LA DÉMYÉLINISATION ET DE
LA DYSMYÉLINISATION ET/OU POUR FAVORISER LA REMYÉLINISATION

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **08.05.2013 US 201361821040 P**

(43) Date of publication of application:
16.03.2016 Bulletin 2016/11

(73) Proprietors:
• **Clene Nanomedicine, Inc.**
North East MD 21901 (US)
• **Zhang, Zhongyan**
North East MD 21901 (US)
• **Mortenson, Mark G.**
North East MD 21901 (US)

(72) Inventors:
• **ZHANG, Zhongyan**
North East, Maryland 21901 (US)
• **MORTENSON, Mark G.**
North East, Maryland 21901 (US)

(74) Representative: **Harris, Oliver John Richard et al**
Novagraaf UK
Centrum
Norwich Research Park
Colney Lane
Norwich NR4 7UG (GB)

(56) References cited:
WO-A1-2011/006007 WO-A1-2011/006007
WO-A2-2012/061828 US-A1- 2006 068 026
US-A1- 2006 207 388 US-A1- 2007 140 966
US-A1- 2008 266 555 US-A1- 2009 169 807
US-A1- 2010 092 470
• **DAN SONNE PEDERSEN ET AL: "Metallic gold slows disease progression, reduces cell death and induces astrogliosis while simultaneously increasing stem cell responses in an EAE rat model of multiple sclerosis", HISTOCHEMISTRY AND CELL BIOLOGY, SPRINGER, BERLIN, DE, vol. 138, no. 5, 22 July 2012 (2012-07-22) , pages 787-802, XP035124374, ISSN: 1432-119X, DOI: 10.1007/S00418-012-0996-2**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- FROHMAN E M ET AL: "MOST PATIENTS WITH MULTIPLE SCLEROSIS OR A CLINICALLY ISOLATED DEMYELINATING SYNDROME SHOULD BE TREATED AT THE TIME OF DIAGNOSIS", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 63, no. 4, 1 April 2006 (2006-04-01), pages 614-619, XP009072802, ISSN: 0003-9942, DOI: 10.1001/ARCHNEUR.63.4.614
- ROMMER P S ET AL: "Monoclonal antibodies in the therapy of multiple sclerosis; An overview", JOURNAL OF NEUROLOGY, STEINKOPFF-VERLAG, DA, vol. 255, no. 6, 1 December 2008 (2008-12-01), pages 28-35, XP019714358, ISSN: 1432-1459
- AKTAS O ET AL: "Neue therapeutische Konzepte bei der multiplen Sklerose /// Novel therapeutic strategies for multiple sclerosis - An overview", NERVENHEILKUNDE, SCHATTAUER, STUTTGART, DE, vol. 29, no. 5, 1 January 2010 (2010-01-01), pages 267-272, XP009182854, ISSN: 0722-1541